TOTAL: $534.42M |
||||
Company (Symbol)# | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised ($M) | Investors; Placement Agents; Details (Date)@ |
Access Pharmaceuticals Inc. (AMEX:AKC) | Private convertible note offering | | $13.5 | Company completed a $13.5M convertible note offering, which was placed with three investors, Philip D. Kaltenbacher, Oracle and an unnamed silent partner (9/20) |
Advanced Tissue Sciences Inc. (ATIS) | Private placement of common stock | 3.5S | $20 | The company placed the shares of unregistered common stock with the State of Wisconsin Investment Board (9/20) |
Advanced Viral Research Corp. (OTC BB:ADVR) | Equity line | | | Company signed a financing contract for a $20M equity line of credit arranged by the May Davis Group (9/27) |
Atlantic Technology Ventures Inc. (ATLC) | Stock purchase agreement | 0.2S | $3 | Investors BH Capital Investments LP and Excalibur Limited Partners agreed to purchase $3M of new Series B convertible preferred stock and warrants to purchase 201,000 shares of Atlantic's common stock (9/29) |
Aviron (AVIR) | Private placement of common stock | 0.24S | $8 | Aviron sold 244,272 shares to Acqua Wellington Asset Management LLC for $8M, or $32.75 per share (9/6) |
Axys Pharmaceuticals Inc. (AXPH) | Private placement of convertible notes and warrants | | $26 | Company agreed to sell $26M aggregate principal amount of 8% senior secured convertible notes maturing on Oct. 1, 2004 (9/21) |
Cambridge Heart Inc. (CAMH) | Private placement of shares and warrants | 3.1S | $8.4 | The company received $8.4M for the sale of 2.4M unregistered shares at $3.50 each and warrants to purchase 716,850 shares also at $3.50 each; the placement was made with a group of institutional investors led by Frontier Capital Management of Boston (9/13) |
Commonwealth Biotechnologies Inc. (CBTE) | Private placement of common stock | | $2.6 | Company completed a $2.6M private placement of common stock and warrants to purchase common stock (9/27) |
Cubist Pharmaceuticals Inc. (CBST) | Issuance of convertible notes | | $39 | Cubist issued $39M in convertible notes to John Hancock Life Insurance Co.; the five-year notes can be converted to stock at a premium to the market price (9/15) |
Enchira Biotechnology Corp. (ENBC) | Private placement of shares and warrants | | $12.8 | Company raised $12.8M through the sale of shares and warrants; financing was led by OrbiMed Advisors LLC and included Oracle Investment Management and Zesiger Capital Group LLC (9/12) |
Epix Medical Inc. (EPIX) | Equity financing facility | | | Company entered into an agreement with Acqua Wellington North American Equities Fund Ltd. for the sale of up to $45M of the company's common stock over the next 28 months (9/18) |
Generex Biotechnology Corp. (GNBT) | Equity line | | | Generex received a commitment from a private investment fund to purchase up to $50M of the company's stock; the commitment was arranged by Ladenburg Thalmann & Co. (9/7) |
Geron Corp. (GERN) | Equity line | | | Geron entered into an agreement with Acqua Wellington North American Equities Fund Ltd. for an equity financing facility covering the sale of up to $50M in company stock over the next 24 months (9/7) |
Labopharm Inc. (TSE:DDS) | Private placement of special warrants | | C$12 (US$8) | The company completed the first tranche of a private placement of special warrants for C$12M with Canadian investors; issue price was $3.05 per special warrant; warrants will convert into common shares on a one-to-one basis (8/31) |
LifeCell Corp. (LIFC) | Private placement of common stock | 2.5S | $10 | LifeCell placed 2.5M shares at $4 per share with selected accredited investors; Prudential Vector Healthcare Group and Gruntal & Co. LLC served as placement agents (9/5) |
NeoTherapeutics Inc. (NEOT) | Private placement of preferred stock | | $5 | Company raised $5M through the private placement of preferred stock that is convertible into a 10% ownership of subsidiary NeoGene Technologies Inc. (9/25) |
Ortec International Inc. (ORTC) | Private placement of common stock | 1.25S | $8.42 | Ortec entered an agreement to sell 1.25M shares to a select group of institutional investors; Stephens Inc. served as placement agent; the financing was led by Franklin Templeton Investments (9/21) |
Palatin Technologies Inc. (AMEX:PTN) | Private placement of stock and warrants | 1.8S | $10.8 | Palatin received $10.8M in the first tranche of a private placement of up to $15M; European financial institutions purchased 1.8M shares at $6 each (9/19) |
Pharmos Corp. (PARS) | Issuance of convertible debentures | | $11 | Pharmos issued $8M in convertible debentures due Feb. 28, 2002, and $3M in common equity, plus warrants exercisable into common stock; Ladenburg, Thalmann & Co. Inc. acted as placement agent (9/6) |
Photogen Technologies Inc. (PHGN) | Equity line | | | Company signed a $40M equity line with Rochelle SA of London and filed a shelf registration statement to draw down the line (9/25) |
Syn X Pharma Inc. (CDNX:SYN) | Private special warrant placement | | $2.9 | Syn X Pharma received the $2.9M held in escrow as part of a private placement announced in August (9/26) |
Vertex Pharmaceuticals Inc. (VRTX) | Sale of convertible subordinated notes | | $345 | Vertex sold $300M of convertible subordinated notes due Sept. 2007 to institutional buyers, who exercised an option to purchase another $45M of notes to cover overallotments; the notes are convertible into Vertex stock at $92.26 per share (9/13) |
Notes: |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||
* Non-U.S. currencies converted at the exchange rate on the date of the announcement. |
||||
@ Dates refer to the date of the press release. |
||||
ASX = Australian Stock Exchange |
||||
LSE = London Stock Exchange |
||||
TSE = Toronto Stock Exchange |
||||
VSE = Vancouver Stock Exchange |
||||
OTC BB = Over The Counter Bulletin Board |
||||